Avastin and docetaxel combo approved for advanced breast cancer in EU
This article was originally published in Scrip
Executive Summary
The European Commission has approved broadening the label of Roche's Avastin (bevacizumab) to allow its use in combination with docetaxel (Sanofi-Aventis's Taxotere) for the first-line treatment of advanced (metastatic) breast cancer.